CRA was retained by the claimant in an ICDR dispute in which a multinational pharmaceutical manufacturer alleged breach of contract by a Latin American distribution partner. CRA’s expert report established that selling prices reported by the distribution partner were inaccurate and undermined the partner’s commitment to provide best efforts in its commercialization activities. The quantum assessment included damages due to lost profits and from lost sales opportunities resulting from the respondent’s failures.
Investment treaty disputes in the life sciences industry
In its global scale and economic impact, the life sciences industry presents unique considerations for investment treaty arbitrations. Recently, the COVID-19...